Delivery Order SPE2DB22D3501-SPE2DB25FWN40
Award Date 7/23/25
Potential Completion Date 8/13/25
Potential Value $3.6K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes valued at $2,881.36, with an ultimate completion date of August 8, 2025. This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used in the treatment of moderate-to-severe...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $2,161.02 and a completion date of June 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order valued at $1,440.70 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on August 4, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, non-set-aside contract employs firm fixed price terms and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used in the treatment of moderate-to-severe allergic asthma and...
- The Defense Logistics Agency awarded a $16,685 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/1.2 ml powder vials. The contract was competitively awarded with no set-aside designation and is scheduled for completion by July 24, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $3,376.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on May 2, 2025, with completion scheduled for May 23, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $34,576.32 delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes, with a completion date of August 22, 2025. This is a firm fixed price, non-set-aside contract awarded on August 1, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a biologic medication used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria, representing a...
- The Defense Logistics Agency awarded a delivery order valued at $5,762.72 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used to treat moderate to severe allergic asthma and other allergic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes valued at $8,644.08 under a firm fixed-price contract. The award was made on July 29, 2025, with an ultimate completion date of August 19, 2025. This is an unset-aside, competitively awarded delivery order issued against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at...
- The Defense Logistics Agency awarded a $2,881.36 delivery order to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes on August 13, 2025, with completion scheduled for September 4, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria, making...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $72,034 firm fixed-price delivery order from the Defense Logistics Agency (DLA) for XOLAIR 150 mg/ml syringes. This competitively awarded contract, with no set-aside designation, is scheduled for completion by May 15, 2025. The delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...